Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly… Continue reading Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

Teligent, Inc. Announces Third Quarter 2020 Results

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020. Financial Highlights Third Quarter 2020 vs. Second Quarter 2020 Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand… Continue reading Teligent, Inc. Announces Third Quarter 2020 Results

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Scheduled to Reconvene on December 16, 2020Company Urgently Encourages Stockholders to Vote BUENA, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November… Continue reading Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Scheduled to Reconvene on November 25, 2020Company Urgently Encourages Stockholders to Vote BUENA, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020 and adjourned to November 11, 2020, was convened and… Continue reading Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Scheduled to Reconvene on November 11, 2020Company Urgently Encourages Stockholders to Vote BUENA, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, was convened and adjourned without any business being conducted… Continue reading Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Teligent Announces Completion of Series D Convertible Note Exchange

BUENA, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senior Notes due 2023 (the “New 2023 Notes”) in exchange for approximately $57.9 million in aggregate principal… Continue reading Teligent Announces Completion of Series D Convertible Note Exchange

Teligent, Inc. Announces Second Quarter 2020 Results

BUENA, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020. Financial Highlights Second Quarter 2020 vs. First Quarter 2020 Revenues of $13.6 million, an increase of $6.1 million or 82%, stronger demand for… Continue reading Teligent, Inc. Announces Second Quarter 2020 Results

Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020

BUENA, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19th, 2020 to discuss the 2nd quarter 2020 financial results and business update. The Company invites you to listen to the call by… Continue reading Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020

Teligent Announces Completion of Series C Convertible Note Financing and Exchange

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Convertible Notes due 2023 (the “New 2023 Notes”). After taking into account an original issue discount and… Continue reading Teligent Announces Completion of Series C Convertible Note Financing and Exchange

Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent’s Board of Directors, replacing James C. Gale who opted to not stand… Continue reading Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board